2016-117 – Mayo Clinic has discovered that the use of USP7 inhibitors sensitize HER2+breast cancer cells to existing HER2+ therapies.
2012-062 – Broad patent claims have issued claiming methods for treating renal cell carcinoma by using SCD1 inhibitors and are available for licensing.
2011-044 – Technology Description Triple reuptake inhibitors (TRIs) are a relatively new class of antidepressants that impact dopamine, serotonin and norepinephrine neurotransmission. Mayo Clinic researchers, in collaboration with researchers from Virginia Tech, developed a novel TRI (PRC200-SS) with potent transporter binding and efficacy in mouse behavioral models. A large pharmaceutical company... Read More
2007-163 – The invention is a series of compounds that block the human transporters for serotonin (hSERT), norepinephrine (hNET), and dopamine (hDAT). Compounds of this series are “triple re-uptake inhibitors” that can be grouped as follows based on their rank-order of potency and affinity at the 3 transporters: 1) potent antagonist of hSERT, hNET, and hDAT with affinity rankings of hSERT (greater than... Read More
2000-090 – Novel small molecule compounds that selectively inhibit norepinephrine, serotonin and dopamine reuptake have been developed. Specifically, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake. The amine compounds provided herein can be used as potent, wide-spectrum antidepressant medications for inhibiting... Read More
2012-098 – Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10%. AA should be further tested for activity against brain tumors.
2005-172 – Serotype selective and nonpeptidic inhibitors of botulinum neurotoxin serotype A (BoNTA) have been developed. These inhibitors are effective in detoxifying botulinum neurotoxin serotype A; they can be used as therapeutics for treating food poisoning by BoNTA, overdose of BoNTA-based cosmetics such as Botox, and they can also be used as countermeausres to BoNTA-based biological weapons.
2000-080 – The treatment of neutrophil-associated pulmonary inflammation including chronic obstructive pulmonary disease (smoker’s bronchitis), chronic bronchitis, cystic fibrosis, alphal-antitrypsin deficiency, adult respiratory distress syndrome and idiopathic pulmonary fibrosis by lidocaine inhalation.